Case O2023_007, scheduled for a hearing on November 11, 2024, revolves around rivaroxaban, a widely prescribed anticoagulant marketed by Bayer as Xarelto®, which has faced increasing competition from generics since mid-2024. The focus of the proceedings is the validity of Bayer's patent concerning a once-daily dosage regimen for rivaroxaban. During the initial hearing, Bayer's legal team, comprising nine members, argued against claims of obviousness based on prior art, including several abstracts and posters from 2003. The court aims to deliver a judgment promptly, potentially before Christmas, amidst ongoing litigation involving similar patent issues.
This news is summarized and processed by the IP Topics artificial intelligence algorithm.
Read the full article on the original webpage: https://www.patentlitigation.ch/bayer-sandoz-main-hearing-re-nullity-of-bayers-rivaroxaban-once-daily-patent/
The cover image belongs to the source website and is used as an integral part of the summary of the reference article.
Tags:
Brevetti